Investors must take note of Trevi Therapeutics Inc’s (TRVI) performance last week, which was 2.02%.

On Tuesday, Trevi Therapeutics Inc (NASDAQ: TRVI) opened higher 0.83% from the last session, before settling in for the closing price of $6.02. Price fluctuations for TRVI have ranged from $2.30 to $7.39 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Company’s average yearly earnings per share was noted -12.27% at the time writing. With a float of $57.14 million, this company’s outstanding shares have now reached $93.60 million.

The extent of productivity of a business whose workforce counts for 26 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Trevi Therapeutics Inc (TRVI) Insider and Institutional Ownership

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Trevi Therapeutics Inc is 40.90%, while institutional ownership is 45.70%. The most recent insider transaction that took place on Mar 25 ’25, was worth 17,365. In this transaction Chief Scientific Officer of this company sold 2,631 shares at a rate of $6.60, taking the stock ownership to the 221,373 shares. Before that another transaction happened on Mar 21 ’25, when Company’s President & CEO sold 5,263 for $6.58, making the entire transaction worth $34,625. This insider now owns 213,313 shares in total.

Trevi Therapeutics Inc (TRVI) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -12.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.24% during the next five years compared to 27.09% growth over the previous five years of trading.

Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators

Check out the current performance indicators for Trevi Therapeutics Inc (TRVI). In the past quarter, the stock posted a quick ratio of 10.41.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.61 in one year’s time.

Technical Analysis of Trevi Therapeutics Inc (TRVI)

The latest stats from [Trevi Therapeutics Inc, TRVI] show that its last 5-days average volume of 0.8 million was inferior to 1.88 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 78.14%. Additionally, its Average True Range was 0.44.

During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 73.76%, which indicates a significant decrease from 78.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.81% in the past 14 days, which was lower than the 101.14% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $5.48, while its 200-day Moving Average is $3.81. Now, the first resistance to watch is $6.22. This is followed by the second major resistance level at $6.37. The third major resistance level sits at $6.49. If the price goes on to break the first support level at $5.95, it is likely to go to the next support level at $5.83. The third support level lies at $5.68 if the price breaches the second support level.

Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats

There are currently 96,682K shares outstanding in the company with a market cap of 586.86 million. Presently, the company’s annual sales total 0 K according to its annual income of -47,910 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -11,420 K.